Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	175.79	94.82	224.95	71.66	171.33	168.13
Short-Term Investments	232.13	196.56	2.5	145.37	0.48	-
Cash & Short-Term Investments	407.92	291.38	227.44	217.03	171.82	168.13
Cash Growth	36.64%	28.11%	4.80%	26.31%	2.19%	190.12%
Accounts Receivable	62.43	46.76	16.62	-	-	-
Other Receivables	1.73	1.3	1.09	3.58	0.09	0.02
Receivables	64.15	48.06	17.71	3.58	0.09	0.02
Inventory	2.71	2.62	3.11	-	-	-
Prepaid Expenses	6	14.65	7.87	4.77	4.05	2.49
Restricted Cash	-	-	-	-	-	0.02
Total Current Assets	480.77	356.71	256.13	225.38	175.95	170.66
Property, Plant & Equipment	3.18	2.87	3.35	1.53	1.83	1.24
Long-Term Investments	3	3	0.86	0.48	0.66	-
Other Intangible Assets	8.09	8.33	3.87	-	-	-
Other Long-Term Assets	5.71	6.09	1.29	0.48	0.46	0.08
Total Assets	500.75	376.99	265.49	227.86	178.91	171.97
Accounts Payable	28.38	27.74	17.77	5.5	2.86	2.24
Accrued Expenses	13.85	19.14	13.9	9.21	7.26	2.87
Current Portion of Leases	0.38	0.61	0.4	0.72	0.61	0.28
Current Income Taxes Payable	-	-	-	-	0.06	-
Current Unearned Revenue	-	-	-	-	0.7	-
Other Current Liabilities	43.69	33.12	4.87	-	-	-
Total Current Liabilities	86.31	80.61	36.94	15.43	11.48	5.39
Long-Term Debt	71.98	71.85	29.82	19.43	-	-
Long-Term Leases	-	-	-	-	0.59	0.55
Other Long-Term Liabilities	-	-	1.75	0.1	0.11	0.06
Total Liabilities	158.29	152.46	68.5	34.96	12.18	5.99
Common Stock	0.01	0.01	0.01	0.01	0	0
Additional Paid-In Capital	727.7	584.56	441.64	301.73	213.4	198.82
Retained Earnings	-385.33	-360.21	-244.66	-108.76	-46.67	-32.85
Comprehensive Income & Other	0.09	0.18	-0	-0.07	-	-
Total Common Equity	342.46	224.53	196.99	192.9	166.73	165.98
Shareholders' Equity	342.46	224.53	196.99	192.9	166.73	165.98
Total Liabilities & Equity	500.75	376.99	265.49	227.86	178.91	171.97
Total Debt	72.37	72.45	30.22	20.16	1.19	0.83
Net Cash (Debt)	335.55	218.92	197.23	196.87	170.62	167.3
Net Cash Growth	25.96%	11.00%	0.18%	15.38%	1.99%	189.50%
Net Cash Per Share	8.69	5.82	6.71	8.00	8.30	26.95
Filing Date Shares Outstanding	42.01	38.38	34.22	26.73	20.71	20.32
Total Common Shares Outstanding	42	38.35	34.21	26.73	20.7	20.32
Working Capital	394.47	276.09	219.2	209.95	164.47	165.27
Book Value Per Share	8.15	5.85	5.76	7.22	8.06	8.17
Tangible Book Value	334.37	216.21	193.12	192.9	166.73	165.98
Tangible Book Value Per Share	7.96	5.64	5.64	7.22	8.06	8.17
Machinery	4.17	3.5	2.08	1.08	0.85	0.54
Leasehold Improvements	0.82	0.79	0.68	0.43	0.13	0.14

Updated May 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q